Blair William & Co. IL Has $5.50 Million Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Key Points

• Blair William & Co. IL increased its ownership of Cardiff Oncology to 1,751,274 shares, raising its stake by 521.0% during the first quarter, valued at $5,499,000.
• Insider Director Gary W. Pace bought 275,000 shares of Cardiff Oncology, boosting his total ownership by 26.05% to 1,330,676 shares, valued at approximately $3.26 million.
• Analysts have mixed ratings for Cardiff Oncology, with a current average rating of "Moderate Buy" and price targets ranging from $3.50 to $19.00 per share.

Blair William & Co. IL raised its holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 521.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,751,274 shares of the company's stock after purchasing an additional 1,469,249 shares during the period. Blair William & Co. IL owned approximately 2.63% of Cardiff Oncology worth $5,499,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in CRDF. Dauntless Investment Group LLC bought a new stake in shares of Cardiff Oncology in the first quarter valued at approximately $302,000. Nuveen Asset Management LLC raised its holdings in Cardiff Oncology by 73.7% in the 4th quarter. Nuveen Asset Management LLC now owns 586,616 shares of the company's stock valued at $2,546,000 after acquiring an additional 248,850 shares in the last quarter. Laurion Capital Management LP bought a new stake in shares of Cardiff Oncology during the 4th quarter valued at $2,504,000. American Century Companies Inc. grew its holdings in shares of Cardiff Oncology by 12.8% during the 4th quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock worth $234,000 after purchasing an additional 6,140 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Cardiff Oncology by 8.9% in the fourth quarter. Northern Trust Corp now owns 337,092 shares of the company's stock worth $1,463,000 after purchasing an additional 27,489 shares during the period. Institutional investors and hedge funds own 16.29% of the company's stock.

Cardiff Oncology Trading Down 0.8%

NASDAQ:CRDF traded down $0.02 on Friday, hitting $2.39. The company had a trading volume of 1,231,296 shares, compared to its average volume of 3,188,633. Cardiff Oncology, Inc. has a 52 week low of $2.09 and a 52 week high of $5.64. The stock has a market capitalization of $159.01 million, a price-to-earnings ratio of -2.75 and a beta of 1.54. The firm has a 50 day moving average of $3.52 and a two-hundred day moving average of $3.46.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.11 million. Cardiff Oncology had a negative return on equity of 77.94% and a negative net margin of 9,344.14%. As a group, equities analysts forecast that Cardiff Oncology, Inc. will post -0.99 EPS for the current year.

Insider Activity

In other Cardiff Oncology news, Director Gary W. Pace acquired 275,000 shares of the company's stock in a transaction that occurred on Wednesday, July 30th. The stock was acquired at an average price of $2.45 per share, for a total transaction of $673,750.00. Following the acquisition, the director directly owned 1,330,676 shares in the company, valued at $3,260,156.20. This represents a 26.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 7.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CRDF shares. HC Wainwright reduced their price objective on shares of Cardiff Oncology from $18.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday. William Blair reaffirmed an "outperform" rating on shares of Cardiff Oncology in a report on Wednesday, June 18th. Jefferies Financial Group assumed coverage on shares of Cardiff Oncology in a research note on Tuesday, June 24th. They issued a "hold" rating and a $3.50 price objective on the stock. Finally, LADENBURG THALM/SH SH assumed coverage on Cardiff Oncology in a report on Tuesday, July 8th. They issued a "buy" rating and a $19.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $10.10.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.